Cortexyme Stock Story

CRTX -  USA Stock  

USD 13.04  1.04  7.39%

Cortexyme Current Liabilities is fairly stable at the moment as compared to the past year. Cortexyme reported Current Liabilities of 17 Million in 2020. Operating Expenses is likely to rise to about 85.1 M in 2021, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (78.5 M) in 2021. As many of us are excited about healthcare space, it is fair to break down Cortexyme. We will cover the possibilities of making Cortexyme into a steady grower in November. This post is to show some fundamental factors affecting Cortexyme's products and services. I will also show how it may impact the investing outlook for Cortexyme in November.
Published over a month ago
View all stories for Cortexyme | View All Stories
Should you hold on to your Cortexyme position?
Over 63.0% of Cortexyme shares are held by institutions such as insurance companies. Institutional ownership of Cortexyme refers to the amount of Cortexyme equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Cortexyme, including its current ownership diagnostics.

How important is Cortexyme's Liquidity

Cortexyme financial leverage refers to using borrowed capital as a funding source to finance Cortexyme ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cortexyme financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cortexyme's total debt and its cash.

How Cortexyme utilizes its cash?

To perform a cash flow analysis of Cortexyme, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cortexyme is receiving and how much cash it distributes out in a given period. The Cortexyme cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Cortexyme Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Cortexyme reported Net Cash Flow from Operations of (50.82 Million) in 2020

What did Cortexyme file with SEC?

The SEC filings are financial statements or other formal documents of Cortexyme that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Cortexyme shareholders may or may not be submitted as SEC does not always require it.
26th of October 2021
Other Events
8th of October 2021
Unclassified Corporate Event
17th of June 2021
Submission of Matters to a Vote of Security Holders
16th of February 2021
Financial Statements and Exhibits. Other Events. Unclassified Corporate Event
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Cortexyme shareholders may or may not be submitted as SEC does not always require it.

Exercise or conversion by Casey Lynch of 60000 shares of Cortexyme subject to Rule 16b-3

Legal trades by Cortexyme insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cortexyme insider trading alert for exercise of stock option (right to buy) by Casey Lynch, Chief Executive Officer, on 19th of November 2021. This event was filed by Cortexyme Inc with SEC on 2021-11-19. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Cortexyme

Cortexyme retains a total of 29.59 Million outstanding shares. Over half of Cortexyme outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Cortexyme. Please watch out for any change in the institutional holdings of Cortexyme as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors3.88

Are you still undecided about Cortexyme?

Cortexyme current total risk alpha rises over 0.51. Cortexyme is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cortexyme independently to ensure intended market timing strategies are aligned with expectations about Cortexyme volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cortexyme's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cortexyme's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on Cortexyme

While other entities in the biotechnology industry are either recovering or due for a correction, Cortexyme may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Cortexyme as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cortexyme.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Cortexyme. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to